Correlation of serum S100B concentration with hospital stay in patients undergoing CABG
| Autor: | Ljuba Krnjak, Primož Trunk, Borut Geršak, Joško Osredkar |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Coronary artery bypass - adverse effects Coronary artery bypass - methods S100 proteins - blood Biological markers - blood Premosnica koronarne arterije - štetni učinci Premosnica koronarne arterije - metode Proteini B100 - krv Biološki biljezi - krv S100 Proteins S100 Calcium Binding Protein beta Subunit Length of Stay Middle Aged Cerebrovascular Disorders Humans Female Nerve Growth Factors Coronary Artery Bypass Biomarkers Aged |
| Zdroj: | Acta clinica Croatica Volume 47 Issue 4 |
| ISSN: | 0353-9466 1333-9451 |
| Popis: | S100B protein has been proposed to be a serum marker of cerebral injury in patients undergoing cardiac surgery. The question to be answered in the present study was whether an increase in serum S100B concentration after the surgery correlated with the length of hospital stay in patients undergoing coronary artery bypass grafting. To answer this question we measured serum S100B concentration preoperatively, at the end of the operation, and on day 1 and day 5 of the surgery in 32 patients undergoing coronary artery bypass grafting. The median (min; max) hospital stay was 7 days (5; 34), and serum S100B concentration was 0.075 mg/L (0.050;0. 095) preoperatively, 0.840 mg/L (0.390; 1.500) immediately after the operation, 0.180 mg/L (0.150;0. 280) on day 1 and 0.100 mg/L (0.080;0. 120) on day 5 of the operation. None of the patients had clinical signs of cerebral injury. Multivariate linear regression analysis indicated serum S100B concentration on day 1 (p=0.0296) and day 5 (p=0.0021) of the operation to correlate with the length of hospital stay independently of the type of operation (with or without the use of cardiopulmonary bypass) and patient clinical characteristics. Our data suggest that serum S100B concentration on day 1 and day 5 of the operation may have prognostic value in patients without clinical signs of cerebral injury. However, this pilot study should be extended to a larger group of patients to confirm this observation. Protein S100B se smatra serumskim biljegom moždanog oštećenja u bolesnika podvrgnutih operacijama srca. U ovom ispitivanju potražili smo odgovor na pitanje korelira li porast serumske koncentracije S100B s duljinom hospitalizacije u bolesnika podvrgnutih ugradnji premosnice koronarne arterije. Serumske koncentracije S100B mjerili smo prije operacije, neposredno nakon operacije, te prvog i petog dana od operacije u 32 bolesnika podvrgnutih ugradnji premosnice koronarne arterije. Medijan (minimum; maksimum) boravka u bolnici bio je 7 (5-34) dana, serumska koncentracija S100B prije operacije 0,075 (0,050; 0,095) µg/L, neposredno nakon operacije 0,840 (0,390; 1,500) µg/L, prvoga dana 0,180 (0,150; 0,280) µg/L i petoga dana nakon operacije 0,100 (0,080; 0,120) µg/L. Nijedan od naših bolesnika nije imao kliničke znakove moždanog oštećenja. Ipak, multivarijantna analiza linearne regresije pokazala je korelaciju serumske koncentracije S100B s trajanjem hospitalizacije prvoga dana (p=0,0296) i petoga dana (p=0,0021) od operacije neovisno o vrsti operacije (uz primjenu kardiopulmonalne obilaznice ili bez nje) i kliničkim značajkama bolesnika. Naši podaci ukazuju na to da bi serumska koncentracija S100B prvoga i petoga dana od operacije mogla imati prognostičku vrijednost u bolesnika bez kliničkih znakova moždanog oštećenja. Ovo naše probno ispitivanje trebalo bi svakako proširiti na veću skupinu bolesnika kako bi se potvrdilo ovo zapažanje. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|